Navigation Links
Salmonella stays deadly with a 'beta' version of cell behavior
Date:8/14/2011

COLUMBUS, Ohio Salmonella cells have hijacked the protein-building process to maintain their ability to cause illness, new research suggests.

Scientists say that these bacteria have modified what has long been considered typical cell behavior by using a beta form of an amino acid as opposed to an alpha form during the act of making proteins.

Beta versions of amino acids occur in nature under rare and specific circumstances, but have never been observed as part of protein synthesis. Before this finding, in fact, researchers had determined that virtually all proteins were constructed with the alpha forms of amino acids.

This work has shown that when researchers delete any one of three genes from the process that makes use of the beta form of the amino acid, or if they insert the alpha form in the beta version's place, Salmonella cells are no longer able to cause disease. The amino acid in question is lysine, one of 22 genetically encoded amino acids that are strung together in cells to make proteins.

"When these genes were knocked out, the cells became sensitive to antibiotics. And if we put beta lysine into the medium where cells were growing, they became resistant to antibiotics," said Michael Ibba, professor of microbiology at Ohio State University and a senior author of the study. "So we could see the beta amino acid being taken up and used. The cells really do need the beta amino acid to be resistant to antibiotics, and for other aspects of their virulence."

This finding suggests that the process using this specific beta amino acid could be an attractive antibiotic target for this common pathogen, the researchers say.

The Centers for Disease Control and Prevention estimates that about 1.4 million people in the United States are infected with Salmonella each year, though only 40,000 cases are reported. Most people infected with Salmonella develop diarrhea, fever and abdomi
'/>"/>

Contact: Michael Ibba
Ibba.1@osu.edu
614-292-2120
Ohio State University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness
2. Yale researchers uncover secrets of salmonellas stealth attack
3. Hygienic Lab at U. Iowa first to confirm salmonella in nationwide outbreak
4. Probiotic without effect against Salmonella
5. Faster Salmonella detection now possible with new technique
6. Mechanism uncovered behind Salmonella virulence and drug susceptibility
7. MU scientist develops salmonella test that makes food safer, reduce recalls
8. Zooming in on the weapons of Salmonella
9. Salmonella utilize multiple modes of infection
10. Bacterium Salmonella enterica regulates virulence according to iron levels found in its surroundings
11. New target found for nitric oxides attack on salmonella bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Hospital Research Institute (OHRI) and the University of Ottawa have ... Spinal muscular atrophy (SMA), the leading inherited cause of death ... student Melissa Bowerman have found that an enzyme called RhoA ... and blocking this enzyme can greatly increase survival. The study ...
... 2010 Using a novel light activation technique, Scripps Research ... a modest ability to fight specific proteins into virtual protein ... capable of inactivating nearby proteins when triggered by light, could ... researchers with a new set of research tools and options. ...
... of psychopaths appear to be wired to keep seeking a ... The research uncovers the role of the brain,s reward system ... understanding what drives these individuals. "This study underscores ... Dr. Francis S. Collins, director of the National Institutes of ...
Cached Biology News:Study opens new avenue for developing treatments for genetic muscle-wasting disease 2Light activated 'warhead' turns modest molecules into super protein killers 2Light activated 'warhead' turns modest molecules into super protein killers 3Psychopaths' brains wired to seek rewards, no matter the consequences 2Psychopaths' brains wired to seek rewards, no matter the consequences 3
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... 21 Startech,Environmental Corp. (OTC Bulletin Board: ... Company, announced today that the,EnviroSafe Industrial Services ... its original plans for its new recycling-facility ... to install three Plasma Converters Systems,purchased last ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... announced that it has elected to suspend,enrolment in ... its Vascular Wrap,product candidate in patients undergoing surgery ... an imbalance of infections that have,been observed between ...
... A group of German,investors is about to acquire up ... purchasing price of up to EUR 750,000. The acquisition,will be ... subscribed,to by the investors. It will become effective after the ... and after the capital increase will,have been entered in the ...
Cached Biology Technology:Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 2Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 4Investors Acquire Share in Sangui BioTech GmbH 2
GOAT ANTI CARICA PAPAYA PAPAIN...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
ANTI MYCOBACTERIUM TUBERCULOSIS...
Biology Products: